Stanford University
Showing 101-150 of 241 Results
-
Byron Lee
Professor of Medicine (Cardiovascular)
BioDr. Byron Lee is Professor of Medicine in the Division of Cardiovascular Medicine and Cardiac Electrophysiology Section. He has published over 150 peer reviewed articles and 10 book chapters. He has written two books to help students navigate the medical school admission process: Insider's Premed Guidebook and Insider's High School Premed Guidebook. His research team studies treatments to prevent sudden cardiac death, atrial fibrillation, and complications of cardiac device lead extraction. He has won numerous teaching awards for his work with medical students, residents, and fellows. He also serves as Chief of Cardiac Electrophysiology at the Palo VA Medical Center and Head Cardiologist for University of California Athletics.
-
David Lee, MD
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly Interests1. Novel treatments and devices for the treatment of valvular disease
2. Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
3. Novel approaches to coronary revascularization
4. Closure devices for atrial septal defects and patent foramen ovale
5. Novel treatments for hypertension -
Eric Leslie
Postdoctoral Scholar, Cardiovascular Medicine
Current Research and Scholarly InterestsTranslational research of exercise responses to improve human health and sport performance. Current research emphasizes multi-omic and accelerometry data analysis to characterize the molecular and applied responses to exercise training as well as the biological profiles of elite athletes.
-
Eleanor Levin
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsCardiovascular Value Based Care, Cardio-Obstetrics, Dyslipidemia Treatment
-
Eldrin F. Lewis, MD, MPH
Simon H. Stertzer, MD, Professor
BioDr. Lewis is a board-certified, fellowship-trained specialist in cardiovascular medicine. He is the chief of the Division of Cardiovascular Medicine and a professor of cardiovascular medicine.
Dr. Lewis is an esteemed clinician-scientist who specializes in the care of patients with advanced heart failure. He is an internationally recognized expert on heart failure, heart transplant, and quality of life for heart failure patients. He cares deeply about his patients as well as his colleagues, the hospital, and the School of Medicine. Dr. Lewis is committed to diversity and inclusion, as well as expanding Stanford clinical research initiatives.
A fundamental principle of Dr. Lewis’ practice is his belief that “there is more to life than death,” that cardiovascular care should go beyond helping patients survive to also helping them enjoy the best possible quality of life.
Dr. Lewis has deep expertise in conducting clinical trials examining diagnostic and therapeutic approaches to heart failure. He has done innovative work to create systems for incorporating quality of life measures for cardiovascular patients into electronic health records. This research has received support from the National Heart, Lung and Blood Institute and the National Institutes of Health.
Much of his quality of life research has focused on patient-reported outcomes. Dr. Lewis emphasizes the importance of looking at how a disease, whether chronic or acute, impacts people’s ability to function and perform their activities of daily living. Strategies to improve patients’ well-being focus not only on their physical symptoms but also on depression, anxiety, exercise capacity, and ability to function in daily living.
Dr. Lewis’ commitment to expanding clinical research initiatives will give patients more opportunities to participate in the clinical trials and access the latest care strategies that can translate into better outcomes. The goal is early access to the most advanced technology, pharmacology, and device therapy that can change outcomes for the better. He also envisions forming closer partnerships with community cardiologists and capitalizing further on Stanford’s proximity to and unique relationships with the digital technology leaders of Silicon Valley to enhance the use of digital technology for monitoring patients, optimizing treatment, and tracking outcomes.
He has authored nearly 200 articles published in peer-reviewed journals including the New England Journal of Medicine, Journal of the American College of Cardiology, Circulation, JAMA Cardiology, JAMA Internal Medicine, and many more. He is also on multiple editorial boards for cardiovascular journals and was an associate editor for Circulation–Heart Failure. In addition, he is an author of professional society clinical practice guidelines and scientific statements from both the American Heart Association (AHA) and the Food and Drug Administration.
Dr. Lewis’ honors for clinical care, scholarship, and research include the Joel Gordon Miller Award for community service and leadership from the University of Pennsylvania School of Medicine. He also was one of the first recipients of the Minority Faculty Development Award, which recognizes the research potential of young physicians. Dr. Lewis has received a grant from the Robert Wood Johnson Foundation to study the role of quality of life assessment in clinical decision making in patients with heart failure.
He is a fellow of the American College of Cardiology and the National American Heart Association (AHA) Research Committee. In addition, Dr. Lewis was as a member of the AHA Founders Affiliate Board of Directors, chair of the Council on Clinical Cardiology, and research chair of the Association of Black Cardiologists. He also serves on scientific committees to review grants for the AHA and on the FDA Task Force for the Standardization of Definitions for Endpoint Events in Cardiovascular Trials. -
Daniel Yuhang Li
Instructor, Medicine - Cardiovascular Medicine
BioI am a physician scientist in the Division of Cardiology at Stanford. My clinical interest is at the intersection of inflammation, autoimmunity and cardiovascular disease in a field called 'Cardio-Rheumatology'. Patients with rheumatologic diseases typically have an elevated cardiovascular disease risk profile along with an insidious onset. Moreover, with the ever-expanding biologic drug formulary for patients, it is important for us to characterize the cardiovascular effects of these medications. In my research, I believe that understanding how inflammatory and autoimmune mechanisms modify coronary artery disease can help us develop a novel perspective towards treating atherosclerosis beyond lipid lowering. My research goal is to advance novel therapeutics for atherosclerosis by leveraging my expertise in genetics, computational biology, and experience with diverse model organism perturbation models. My strategy employs a ‘systems’ approach, starting with human population variations at the genetic level and integrating findings across RNA, protein, and model organism studies. This comprehensive synthesis aims to grasp the overarching biological narrative, thereby facilitating the development of translational therapies that transform concepts from bench to bedside.
-
Ronglih Liao
Douglass M. and Nola Leishman Professor of Cardiovascular Disease
BioDr. Liao is a Professor of Medicine and co-Director of Stanford Cardiac Amyloid Center. The major goal of her research program focuses on understanding the mechanisms that underlie the pathophysiology of heart failure and developing novel treatments to combat this process. Her laboratory has played an international leading role in the study of amyloid light chain (AL) cardiomyopathy, a rare and fatal form of cardiovascular disease. We have described the underlying pathophysiologic basis for amyloid cardiomyopathy and found that the circulating amyloidogenic light chain proteins that characterize this disease directly result in a specific cardiotoxic response. Consequently, our research work has redefined AL cardiomyopathy and has raised new treatment approaches. More recently, her research efforts have expanded to include transthyretin (ATTR) cardiac amyloidosis.
In line with her goal of revealing novel therapeutic strategies for patients with cardiovascular disease, our efforts have also focused on characterizing and harnessing endogenous cardiac regenerative mechanisms. Her laboratory initially demonstrated the therapeutic potential of exogenous primitive muscle cells delivered to the injured heart. This work was among the earliest milestones in the field and served as the basis for an international trial of cell-based therapy. Subsequently, Liao lab identified and characterized a population of cardiac progenitor cells and its relationship and dynamic activity following cardiac injury in the adult heart. Her laboratory aims to reveal the molecular mechanisms regulating the endogenous regenerative capacity of the heart and to harness such repair mechanisms for the treatment of cardiovascular disease. Dr. Liao has lectured extensively on both amyloid cardiomyopathy and stem cell biology, and have maintained a history of independent NIH funding in these areas for more than two decades.
Over the course of her academic career, she has taken the greatest pride in mentoring the next generation of scientists. Dr. Liao has had the privilege to supervise several dozen students, postdoctoral fellows, and junior faculty, many of whom have gone on to independent academic careers at the highest institutions. Her contribution to the advancement of scientific knowledge also includes lecturing at various university and academic institutions as well as at scores of conferences and symposia locally, nationally, and internationally. -
Malene Lindholm
Sr. Research Engineer, Medicine - Med/Cardiovascular Medicine
Current Research and Scholarly InterestsInterested in the genetics of human performance and the multi-omic response to exercise and training for optimizing human health.
-
George Lui
Clinical Professor, Medicine - Cardiovascular Medicine
Clinical Professor, Pediatrics - CardiologyCurrent Research and Scholarly InterestsAdult Congenital Heart Disease
-
Kenneth Mahaffey
Professor of Medicine (Cardiovascular Medicine)
BioClinical Focus: Cardiovascular Medicine: Atrial Fibrillation; Chronic CAD; ACS;
Research Focus:
My primary research interest is the design and conduct of multicenter clinical trials and analyses of important clinical cardiac issues using large patient databases. My research focuses on novel anticoagulation agents for the treatment of acute coronary syndromes and atrial fibrillation, the study of agents targeted to protect the myocardium during reperfusion therapy for acute myocardial infarction, and the evaluation of cardiovascular safety of diabetic therapies. I am also interested in the methodology of clinical trials. Current research activities include standardization of the definition of myocardial infarction used in clinical trials, the adjudication of suspected clinical endpoint events by Clinical Event Committees (CEC), and the efficient operational conduct of large multinational clinical trials.
Administrative Focus: Associate Dean, Clinical Research School of Medicine; Vice Chair of Clinical Research Department of Medicine; Director Stanford Center for Clinical Research; Member of the Stanford IRB
Professional Training:
1985 Stanford University, BS Chemistry
1989 University of Washington, MD
1993 University of Arizona, Internship/Residency/Chief Residency
1996 Duke University, Fellowship in Cardiology
1996 Duke University, Faculty in Cardiology
2013 Stanford University, Faculty Cardiovascular Medicine -
Anurag Mairal
Adjunct Professor, Medicine - Cardiovascular Medicine
BioDr. Anurag Mairal is an Adjunct Professor of Medicine and the Director, Global Outreach Programs at Stanford Mussallem Center for Biodesign, Stanford University. He is also a Faculty Fellow and Lead for Technology Innovation and Impact at Center for Innovation in Global Health. In these roles, he leads initiatives focused on applying the biodesign process to resource-constrained settings globally. Further, he facilitates opportunities for students, faculty and fellows at Stanford to work on global healthcare needs. He is founding co-Director for MED 232, Global Health: Scaling Health Technology Innovations in Low Resource Settings, and was part of the founding faculty team for BIOE 371, Global Biodesign: Medical Technology in an International Context, graduate-level courses offered to engineering, business, and medical students at Stanford University. Earlier, he served as Associate Director for the Stanford-India Biodesign and Singapore-Stanford Biodesign programs. He serves as the Founding Chair of BME IDEA APAC, a community of medtech innovation programs in Asia Pacific, partnering closely with the industry and academia in the region. He is also an Honorary Professor at University of Cape Town, South Africa. Concurrently, he is a co-founder and Executive Vice President of Orbees Medical, a SF Bay Area-based strategy consulting firm serving global healthcare industry, with a focus on medtech, pharmaceutical, and digital health industry.
Dr. Mairal has an extensive background in medical technology development and commercialization, collaborating with partners in the U.S., India, China, and other emerging markets to advance product development, manufacturing, and distribution. Recently, he took a sabbatical for two years to take a senior leadership role at PATH, a major global health nonprofit based in Seattle. In this role, he oversaw research and development, commercialization, and implementation of technologies in PATH’s medical devices, diagnostics, and digital health divisions. Previously, he held several positions at Johnson & Johnson, including Business Development Director and Product Director for structural heart, cardiology, and peripheral vascular products at Cordis. Before joining J&J, he was a Group Leader and a Process Development Manager at Membrane Technology and Research (MTR). At MTR, he was responsible for business development, strategic alliances, and product development in the bioseparations area. An active mentor to entrepreneurs and industry professionals, he serves as the chair of PATH’s Bay Area Leadership Council; co-chair of the global advisory board at EPPIC Global Network; chair of Faculty Alumni Network and member of the Board Executive Committee at IIT Bombay Heritage Foundation; and President of Sewa International - Bay Area.
Dr. Mairal earned a PhD in chemical engineering from the University of Colorado at Boulder and an MBA from the Haas School of Business at the University of California at Berkeley. He also holds an MS in chemical engineering from the Indian Institution of Technology in Mumbai and a BS in chemical engineering from National Institute of Technology, Raipur. Dr. Mairal was a post-doctoral fellow at the University of Twente, Netherlands and at University of Michigan, Ann Arbor. At BerkeleyHaas, he was a founding co-Chairman of the South Asia Business Conference and Chair of the Biotech Panel for the Asia Business Conference. His work has been published in more than 30 publications, and he has seven issued patents. -
Joshua Makower
Yock Family Professor and Professor of Bioengineering
Current Research and Scholarly InterestsDr. Josh Makower is the Boston Scientific Applied Bioengineering Professor of Medicine and of Bioengineering at the Stanford University Schools of Medicine and Engineering and the Director of the Stanford Byers Center for Biodesign, the program he co-founded with Dr. Paul Yock twenty years ago. Josh helped create the fundamental structure of the Center’s core curriculum and is the chief architect of what is now called “The Biodesign Process.” Over the past 20 years since Josh and Paul founded Biodesign, this curriculum and the associated textbook has been used at Stanford and across the world to train hundreds of thousands of students, faculty and industry leaders on the Biodesign process towards the advancement of medical innovation for the improvement of patient care. Josh has practiced these same techniques directly as the Founder & Executive Chairman of ExploraMed, a medical device incubator, creating 9 companies since 1995. Transactions from the ExploraMed portfolio include NeoTract, acquired by Teleflex, Acclarent, acquired by J&J, EndoMatrix, acquired by C.R. Bard & TransVascular, acquired by Medtronic. Other ExploraMed/NEA ventures include Moximed, NC8 and Willow. Josh is also a Special Partner at NEA where he supports the healthcare team and medtech/healthtech investing practice. Josh serves on the boards of Allay Therapeutics, Revelle Aesthetics, Setpoint Medical, DOTS Technologies, Eargo, ExploraMed, Intrinsic Therapeutics, Moximed, Willow and Coravin. Josh holds over 300 patents and patent applications. He received an MBA from Columbia University, an MD from the NYU School of Medicine, a bachelor’s degree in Mechanical Engineering from MIT. Josh is a Member of the National Academy of Engineering and the College of Fellows of The American Institute for Medical and Biological Engineering and was awarded the Coulter Award for Healthcare Innovation by the Biomedical Engineering Society in 2018.
-
Neha Maheshwari Mantri
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Neha Mantri serves as the Director of the Structural Imaging Program and Director of the Women’s Cardiology Clinic at Palo Alto VA Health Care System (PAVA HCS). Given her expertise in advanced imaging, she serves as a reader in the Echocardiography Lab at Stanford Hospital. She also leads several echocardiography quality improvement projects, weekly multi-modality imaging educational seminars, and fellow workshops across the PAVA HCS and Stanford echo labs.
-
Michael V. McConnell, MD, MSEE
Clinical Professor, Medicine - Cardiovascular Medicine
Current Research and Scholarly InterestsMy imaging research has involved clinical and molecular Imaging of cardiovascular disease, with a focus on coronary and vascular diseases, including atherosclerosis, aortic aneurysms, and vascular inflammation.
My prevention research has involved innovative technologies to reduce coronary and vascular disease, including early disease detection plus leveraging mobile health and AI to enhance heart heart in patients and populations. -
Jessica Lee Mega
Affiliate, Medicine - Med/Cardiovascular Medicine
BioJessica L. Mega, MD, MPH is a leader at the intersection of technology, life science, and health. She is a Cardiologist at Stanford and serves on the Advisory Board for Stanford's Center for Digital Health. She is a Co-Founder of Alphabet's Verily and former Chief Medical Officer of Google Life Sciences. She is on the Board of Directors at Boston Scientific and Danaher Corporation, as well as the Board of Advisors for Research!America and the Duke-Margolis Center for Health Policy. She is a Senior Advisor at SandboxAQ and the Chair of the Investment Committee of the American Heart Association’s GRFW Venture Fund.
As a faculty member at Harvard Medical School, a Senior Investigator with the TIMI Study Group, and a Cardiologist at Brigham and Women’s Hospital, Dr. Mega led large, international, randomized trials evaluating novel therapies and new medical technologies. She directed the TIMI Study Group’s Genomics Program, demonstrating and testing the role of CYP2C19 genetic variants on antiplatelet medications, a key pharmacogenetic finding. She has published manuscripts in the New England Journal of Medicine, Lancet, and JAMA. She served as an Advisor for the California Governor’s Precision Medicine Initiative.
Dr. Mega is a graduate of Stanford University, Yale University School of Medicine, and Harvard School of Public Health. She completed Internal Medicine Residency at Brigham and Women’s Hospital and Cardiovascular Fellowship at Massachusetts General Hospital. She is board certified in Internal Medicine and Cardiology. She has won the Laennec Society, Samuel A. Levine, and Douglas P. Zipes Awards, and she is a Fellow of the American Heart Association and the American College of Cardiology. -
Hector Mendez
Postdoctoral Scholar, Cardiovascular Medicine
BioDr. Hector Rodrigo Mendez is a Medical Geneticist from Argentina. Rodrigo completed a residency program in Medical Genetics at Centro Nacional de Genetica Medica – ANLIS (Buenos Aires, Argentina) and a Master’s program in Medical Molecular Biology at Buenos Aires University.
Rodrigo continued his scientific career at a German Genomic Start-up, working as a human geneticist and providing his experience in rare disorders, genomic data (WGS/WES/gene panels) analysis, variant interpretation, and its integration with a deep focus on genotype-phenotype correlation.
Rodrigo’s areas of expertise are rare disorders, NGS technology, Whole Genome Sequencing analysis, and ACMG interpretation guidelines, and his research aims are:
- Collection and analysis of clinical data through deep-learning phenotyping approaches.
- Multi-omic data integration to elucidate complex and rare genetic disorders.
- Drive progress in curing rare genetic diseases, particularly among critically sick infants.
At Stanford University, under the supervision of Dr. Matthew Wheeler, he is conducting his postdoctoral research studies to achieve his scientific goals. -
Mark Mercola
Professor of Medicine (Cardiovascular) and, by courtesy, of Chemical and Systems Biology
BioDr. Mercola is Professor of Medicine and Professor in the Stanford Cardiovascular Institute. He completed postdoctoral training at the Dana-Farber Cancer Institute and Harvard Medical School, was on the faculty in the Department of Cell Biology at Harvard Medical School for 12 years, and later at the Sanford-Burnham-Prebys Institute and Department of Bioengineering at the University of California, San Diego before relocating to Stanford in 2015.
Prof. Mercola is known for identifying many of the factors that are responsible for inducing and forming the heart, including the discovery that Wnt inhibition is a critical step in cardiogenesis that provided the conceptual basis and reagents for the large-scale production of cardiovascular tissues from pluripotent stem cells. He has collaborated with medicinal chemists, optical engineers and software developers to pioneer the use of patient iPSC-cardiomyocytes for disease modeling, safety pharmacology and drug development. His academic research is focused on developing and using quantitative high throughput assays of patient-specific cardiomyocyte function to discover druggable targets for preserving contractile function in heart failure and promoting regeneration following ischemic injury. He co-established drug screening and assay development at the Conrad Prebys Drug Discovery Center (San Diego), which operated as one of 4 large screening centers of the US National Institutes of Health (NIH) Molecular Libraries screening initiative and continues as one of the largest academic drug screening centers.
Prof. Mercola received an NIH MERIT award for his work on heart formation. He holds numerous patents, including describing the invention of the first engineered dominant negative protein and small molecules for stem cell and cancer applications. He serves on multiple editorial and advisory boards, including Vala Sciences, Regencor, The Ted Rogers Centre for Heart Research and the Human Biomolecular Research Institute. His laboratory is funded by the National Institutes of Health (NIH), California Institute for Regenerative Medicine, Phospholamban Foundation and Fondation Leducq. -
Samuel Montalvo
Postdoctoral Scholar, Cardiovascular Medicine
BioAs a clinical exercise physiologist and sport biomechanist, I am dedicated to advancing human exercise and sports performance. I hold certifications as a Performance and Sport Scientist (CPSS) and as a Strength and Conditioning Specialist with Distinction (CSCS, *D) from the National Strength and Conditioning Association (NSCA). In 2022, I was honored with the Wu Tsai Human Performance Alliance Post-Doctoral Research Fellowship and a T32 Post-Doctoral Fellowship, Research Training in Myocardial Biology (TIMBS) at Stanford University.
My research focuses on understanding the mechanical, molecular, and physiological mechanisms that underpin human performance. I am also committed to developing innovative and practical training methods to enhance exercise and sports performance. Currently, I am a member of the Stanford Bioinformatics Core, contributing to the NIH-funded Molecular Transducers of Physical Activity Consortium (MoTrPAC) project. In this capacity, I analyze extensive clinical and exercise datasets, as well as multi-omic, multi-tissue, multi-exercise modality, and multi-species data, to uncover new insights into the biological mechanisms of physical activity and its impact on human health and performance.
In addition to my primary research focus, I collaborate with several teams at Stanford on projects involving Sports and Electrocardiography, Cardiopulmonary Exercise Testing, Exercise and Neuromuscular Disease, and the Stanford Baseball Team.
Beyond research, I am deeply committed to teaching and mentoring. As a first-generation college graduate and a Mexican-American with Indigenous heritage, I bring a unique perspective to my work, which informs my dedication to creating supportive and inclusive spaces for underrepresented groups in science and education. I serve as a Post-Doc Mentoring Coach in collaboration with the Stanford Office of Postdoctoral Affairs, where I facilitate bi-weekly workshops on mentoring for postdocs. I am also part of the Stanford PRISM program, which promotes opportunities for postdoctoral scholars. Furthermore, I mentor prospective and current medical students through the MAVERICs program (Metascience Analyses and Explorations of Reproducibility in Cardiovascular Science) as part of the Stanford Cardiovascular Institute, supporting their growth in cardiovascular research.
These experiences reflect my dedication to fostering an inclusive and supportive academic environment. My long-term goal is to become a professor, combining my passion for research, education, and mentoring the next generation of scientists to advance the fields of exercise physiology, multi-omics, and sports science. -
Tia Moscarello, MS, LCGC
Staff, Medicine - Med/Cardiovascular Medicine
Clinical Assistant Professor (Affiliated), Pediatrics - GeneticsBioLicensed and certified genetic counselor with a specialization in inherited cardiovascular disease. Primary genetic counselor for the first on-call cardiovascular genetic counseling service. Clinical instructor for the Stanford University MS in Human Genetics and Genetic Counseling Program.
-
Jonathan N. Myers
Clinical Professor (Affiliated), Medicine - Med/Cardiovascular Medicine
BioDr. Myers is a Health Research Scientist at the Palo Alto VA Health Care System; a Clinical Professor at Stanford University (Affiliated), and a Senior Research Career Scientist Award recipient through the VA Rehabilitation Research and Development Program. His research has focused on primary and secondary prevention, and the clinical applications of exercise testing and rehabilitation in patients with cardiovascular disease and other chronic conditions. He has a lengthy history of studying the epidemiology of cardiopulmonary exercise test responses, physical activity patterns, and other lifestyle factors and their relation to health outcomes. He manages the Veterans Exercise Testing Study (VETS), an ongoing, prospective evaluation of Veteran subjects referred for exercise testing for clinical reasons, designed to address exercise test, clinical, and lifestyle factors and their association with health outcomes.
He earned his bachelor’s degree from the University of California, Santa Barbara, his master's degree from San Diego State University, and his doctorate from the University of Southern California. He has been a board member for many organizations including the American Heart Association (AHA), the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR), and the American College of Sports Medicine (ACSM), and serves on the editorial board for 9 journals. He is a recipient of the Michael Pollock Established Investigator Award through the AACVPR, a recipient of the Steven N Blair Award for excellence in physical activity research from the AHA Council on Epidemiology and Prevention and is the 2022 recipient of the American College of Sports Medicine Citation Award. He is a fellow of the AACVPR, ACSM, American College of Cardiology, and the AHA, and has authored and co-authored guidelines on exercise testing and rehabilitation for each of these organizations, including the 2021 editions of the ACSM and AACVPR guidelines. -
Sanjiv Narayan
Professor of Medicine (Cardiovascular Medicine)
Current Research and Scholarly InterestsDr. Narayan directs the Computational Arrhythmia Research Laboratory, whose goal is to define the mechanisms underlying complex human heart rhythm disorders, to develop bioengineering-focused solutions to improve therapy that will be tested in clinical trials. The laboratory has been funded continuously since 2001 by the National Institutes of Health, AHA and ACC, and interlinks a disease-focused group of clinicians, computational physicists, bioengineers and trialists.
-
Minh Nguyen
Contingent Employee, Medicine - Med/Cardiovascular Medicine
BioPrevious bio as a PhD student:
@DARE fellow (Diversifying Academia, Recruiting Excellence) https://vpge.stanford.edu/people/minh-nguyen
@Data Science Scholar https://datascience.stanford.edu/people/minh-nguyen -
Koen Nieman
Professor of Medicine (Cardiovascular Medicine) and of Radiology (CV Imaging)
Current Research and Scholarly InterestsDr Nieman investigates advanced cardiac imaging techniques. Current projects focus on the development of functional CT application for hemodynamic interpretation of coronary artery disease, and the clinical validation of cardiac CT in the management of patients with ischemic heart disease.
-
Joyce Njoroge, MD
Clinical Assistant Professor, Medicine - Cardiovascular Medicine
BioDr. Njoroge is a board-certified physician and fellowship-trained cardiologist with the Advanced Heart Failure Program at Stanford Health Care. She is also a clinical assistant professor of medicine in the Division of Cardiovascular Medicine.
Dr. Njoroge has extensive clinical experience diagnosing and treating cardiovascular complications that develop during pregnancy or postpartum. She currently provides care at the Stanford Health Care Heart and Vascular Clinic with a particular focus on patients with a history of pregnancy-associated heart failure and cardiomyopathy.
Dr. Njoroge’s research efforts involve identifying inherited genetic changes and biological markers that could help improve screening and care for pregnant women in higher risk populations. This includes determining the causes of disproportionately high incidences of heart-related complications and deaths experienced by Black women during and after pregnancy. Dr. Njoroge is also currently recruiting patients for a large-scale, multicenter clinical trial evaluating a drug to treat cardiovascular complications during pregnancy.
Dr. Njoroge has published her work in numerous prestigious peer-reviewed journals, including Circulation Research and the Journal of Cardiac Failure. She also co-authored a chapter on cardiovascular disease in pregnancy in the most recent edition of the book Current Diagnosis and Treatment: Cardiology.
Dr. Njoroge is a member of the Association of Black Cardiologists, the American College of Cardiology, the American Heart Association, and the Heart Failure Society of America. -
Connor Galen O'Brien
Postdoctoral Medical Fellow, Cardiovascular Medicine
BioDr. O'Brien is a native of Menlo Park, CA. He attended medical school at Columbia University College of Physicians and Surgeons. At Columbia he was elected to both Alpha Omega Alpha and Gold Humanism Honors Societies. He completed an Internal Medicine residency as well as fellowship in Cardiovascular Medicine at Stanford University. In his third year of fellowship, he was selected Chief Cardiology Fellow.
He is currently a post-doctoral fellow performing regenerative medicine research, specifically studying the role of exosomes in treating cardiomyopathy. In addition to his basic science research, he is also involved in human clinical trials investigating the role of stem cells in treating various forms of cardiomyopathy. -
Latha Palaniappan, MD, MS
Professor of Medicine (Cardiovascular Medicine) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsDr. Palaniappan has published over 200 peer reviewed manuscripts, abstracts, and book chapters over the last 20 years in the areas of chronic disease prevention and treatment in diverse populations. She has expertise in epidemiological research using big data, use of electronic health records for research, and clinical trials.
